News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cambridge-Based Biotech Isogenica Limited Announces New Partnership with Phylogica Ltd.


2/2/2010 10:03:08 AM

CAMBRIDGE, England--(BUSINESS WIRE)--Isogenica Ltd today announced that it has entered into an agreement with Australian based biopharmaceutical company Phylogica to use Isogenica’s CIS display technology to optimize the performance of three of Phylogica’s lead compounds targeting CD40 ligand (CD40L). CD40L is a key protein involved in many inflammatory diseases, such as Rheumatoid Arthritis and Inflammatory Bowel Disease.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES